Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

• Status: Not yet recruiting
• Trial end date: 2025-08-30
• Target enrollment: 0
• Participant gender: All

Summary

To assess the outcomes of NRM when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC) and an allogeneic stem cell transplant (allo-SCT) and post-transplant graft-versus-host disease prophylaxis based on post-transplant cyclophosphamide (PT-Cy) in patients with inherited blood disorders.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Bortezomib; Busulfan; Cyclophosphamide; Cyclosporine; Cyclosporins; Dexamethasone; Fludarabine; Mycophenolic Acid; Rituximab; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria:

1. The first six patients will be ages >12 years old and <35 years old. Thereafter in a second stage, patients ages 2 to 50 years old will be included.

2. Patient with a matched related donor or who has a related haploidentical donor identified.

3. Performance score of at least 70 by Karnofsky or 0 to 1 by ECOG (age > 12 years), or Zubrod or Lansky Play Performance Scale of at least 70 (age <12 years).

4. Adequate major organ system function as demonstrated by:

1. Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockroft-Gault formula).

2. Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT and/or AST equal or less than 3x institutional ULN. Conjugated (direct) bilirubin less than 2x upper limit of normal.

3. Left ventricular ejection fraction equal or greater than 50%.

4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50%

5. Predicted, corrected for hemoglobin. For children < 7 years of age who are unable to perform PFT, oxygen saturation > 92% on room air by pulse oximetry.

5. Patient or the patient's legal representative, parent(s) or guardian should be able to provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years.

6. Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator.

Exclusion Criteria:

1. HIV positive; active hepatitis B or C.

2. Uncontrolled infections.

3. Liver cirrhosis. However mild fibrosis will be allowed i.e. fine reticulin or Grade 1, with bridging fibrosis.

4. CNS involvement within 3 months.

5. Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.

6. Inability to comply with medical therapy or follow-up.

7. Will restrict eligibility to a maximum BMI of ≤40

8. Patient with a known history of allergic reactions to any constituents of the cell product, including a known history of allergic reactions to DMSO.

9. Prior allo-SCT

10. Other active malignancy/cancer diagnosis in remission for at least 2yrs. Malignancies not being excluded are as follows: Ductal carcinoma in situ (DCIS), Basal cell carcinoma (BCC), Cervical intraepithelial neoplasia (CIN)